MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes

Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.

Laboratories that run molecular diagnostic tests were not surprised by the revised reimbursement rates that CMS recently released for new molecular pathology codes including the 2014 National Limit Amount, but they are concerned that the agency only posted revised reimbursement rates for 65 of the original 114 new codes slated for pricing under the “gap-filling” method.

Along with the revised 2013 payment amounts for molecular pathology codes established by local Medicare administrative contractors, CMS...

More from Archive

More from Medtech Insight

Finland Cracks Down On Software That Needs Regulating As A Medical Devices

 

Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it. 

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.